## Diagnostic Uncertainty in Intermediate-Risk Nodules **Key Point:** A nodule 1–2 cm with arterial enhancement but WITHOUT definite washout on one imaging modality does NOT meet diagnostic criteria for HCC. A second imaging modality is required. ### AASLD Diagnostic Algorithm for Nodules 1–2 cm ```mermaid flowchart TD A[Nodule 1-2 cm on US]:::outcome --> B{Arterial enhancement<br/>on CT/MRI?}:::decision B -->|No| C[Benign lesion<br/>Continue surveillance]:::outcome B -->|Yes| D{Washout on same<br/>modality?}:::decision D -->|Yes| E[HCC diagnosed<br/>Proceed to staging<br/>& treatment]:::action D -->|No| F[Get second imaging<br/>modality]:::action F --> G{Arterial + washout<br/>on 2nd modality?}:::decision G -->|Yes| E G -->|No| H[Biopsy OR<br/>Surveillance]:::decision ``` **High-Yield:** For nodules 1–2 cm, arterial enhancement + washout on **TWO** imaging modalities is required for diagnosis. If only one modality shows both features, a second imaging study is mandatory. ### Why MRI is the Best Second Modality Here 1. **Complementary imaging:** MRI with hepatobiliary contrast (gadoxetate) has superior sensitivity for detecting washout in small nodules 2. **Tissue characterization:** Hepatobiliary contrast agents provide additional information (hepatobiliary phase) unavailable on CT 3. **No additional radiation:** Unlike repeat CT, MRI avoids radiation exposure 4. **High diagnostic accuracy:** MRI detects washout in >80% of HCCs when CT is equivocal **Clinical Pearl:** Gadoxetate-enhanced MRI is the gold standard for resolving diagnostic uncertainty in nodules 1–2 cm with equivocal CT findings. **Warning:** Do NOT diagnose HCC on arterial enhancement alone in a nodule <2 cm without washout confirmation. This leads to overdiagnosis and unnecessary treatment. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.